India, April 28 -- Image credit- shutterstock

Aurigene Pharmaceutical Services announced a $100 million investment plan, earlier this year to accelerate growth in its CRDMO services across Small molecules, Peptides, Nutraceuticals and Biologics.

In the first phase, Aurigene has deployed $40 million for their Genome Valley site at Hyderabad. This facility is designed to serve the cell line, clinical development & small-scale manufacturing of biologics assets of innovative biotechs and pharmaceutical manufacturers.

The company has disclosed the details regarding the next phase of investment of around $60 million.

Aurigene has deployed $20 million in building a state-of-the-art API & Intermediates block, adding more capacity at one of it...